Drug Profile


Alternative Names: HBAI 20 - CyTuVax; HBAI-20

Latest Information Update: 10 May 2016

Price : $50

At a glance

  • Originator CyTuVax
  • Class Hepatitis B vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Hepatitis B

Most Recent Events

  • 29 Apr 2016 Interim immunogenicity and adverse events data from a phase I trial in Hepatitis B infection released by CyTuVax
  • 29 Apr 2016 CyTuVax plans a phase II study in Hepatitis B
  • 01 Sep 2015 Phase-I clinical trials in Hepatitis B prevention in Netherlands (Parenteral) (NCT02540538)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top